Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALORA vs ANDROID-F
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.
Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.
Moderate to severe vasomotor symptoms due to menopause,Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prostate cancer (palliative),Breast cancer (palliative, in selected cases),Postpartum breast engorgement (prevention)
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.
Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.
The terminal elimination half-life of estradiol is approximately 13-19 hours following transdermal administration, reflecting slow release from the skin depot and ongoing metabolism. This half-life allows for continuous hormone levels with once- or twice-weekly dosing.
2.5-3.5 hours (terminal half-life); oral administration may require multiple daily doses for stable levels.
Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates (glucuronides and sulfates).
Metabolized primarily by CYP4F2, with minor contributions from CYP2D6, CYP2E1, CYP3A4, and CYP1A2. Undergoes biotransformation to an inactive metabolite.
Alora (estradiol transdermal system) is eliminated primarily via hepatic metabolism, with approximately 60% of a dose excreted in urine as glucuronide and sulfate conjugates, and about 40% excreted in feces via biliary elimination.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); small amount biliary/fecal.
Estradiol is approximately 97-99% bound to serum proteins, primarily sex hormone-binding globulin (SHBG) and albumin. The binding to SHBG is high affinity, while albumin binding is nonspecific and lower affinity.
97-99% bound to sex hormone-binding globulin (SHBG) and albumin.
The apparent volume of distribution (Vd) of estradiol is approximately 5-10 L/kg, indicating extensive distribution into tissues including breast, adipose, and reproductive organs. This large Vd reflects sequestration in adipose tissue and other estrogen-sensitive tissues.
0.5-0.8 L/kg; reflects distribution into muscle, liver, and reproductive tissues.
The bioavailability of estradiol from the transdermal system is approximately 10% compared to oral administration, due to avoidance of first-pass hepatic metabolism. The absolute bioavailability relative to intravenous is near 100%, as transdermal delivery provides direct systemic absorption.
Oral: 3-6% (extensive first-pass metabolism); IM: 100%.
No dose adjustment required for mild-moderate renal impairment (GFR >=30 m L/min). Not studied in severe impairment (GFR <30 m L/min); use with caution.
GFR 10-50 m L/min: reduce dose by 50%. GFR <10 m L/min: avoid use.
Contraindicated in severe hepatic disease (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use lowest effective dose and monitor. No adjustment for mild (Child-Pugh class A).
Child-Pugh A: reduce dose by 50%. Child-Pugh B: avoid use. Child-Pugh C: contraindicated.
Not approved for use in pediatric patients. Safety and efficacy not established.
Not recommended for use in children due to risk of premature epiphyseal closure and virilization.
Use lowest effective dose and duration. Consider increased risk of cardiovascular events, thromboembolism, and malignancy. Starting dose 0.025 mg/day with gradual titration as needed.
Use with caution; consider lower starting dose due to increased risk of fluid retention, hypertension, and prostatic hypertrophy in males.
Estrogens increase the risk of endometrial cancer. Unopposed estrogen increases the risk of endometrial hyperplasia and carcinoma. Adequate diagnostic measures, including endometrial sampling if indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
Risk of bradyarrhythmia and atrioventricular block, requiring first-dose monitoring for 6 hours. Fatal infections, including opportunistic infections, have occurred. Macular edema has been reported.
Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism), probable dementia (increased risk in women ≥65 years), breast cancer, endometrial cancer, gallstones, hypertriglyceridemia, fluid retention, hypocalcemia, hereditary angioedema, and exacerbation of endometriosis.
May cause bradycardia and AV block; monitor heart rate after first dose. Increased risk of infections, including herpes viruses and cryptococcal meningitis. Macular edema, especially in patients with diabetes or uveitis. Posterior reversible encephalopathy syndrome (PRES). Respiratory effects, including decreased FEV1 and DLCO. Hepatic injury; monitor liver enzymes.
Undiagnosed abnormal genital bleeding, known/suspected pregnancy, known/suspected breast cancer (except in selected cases), known/suspected estrogen-dependent neoplasia, active DVT/PE or history of these conditions, active arterial thromboembolic disease, known protein C/protein S/antithrombin deficiency or other thrombophilic disorders, liver dysfunction or disease, known hypersensitivity to estradiol or any component.
Recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure, history of Mobitz type II 2nd or 3rd degree AV block, sick sinus syndrome unless pacemaker is present, or severe untreated sleep apnea.
No significant food interactions. Avoid grapefruit juice if on hormonal therapy as it may increase estrogen levels.
No significant food interactions reported. Avoid excessive alcohol consumption due to hepatotoxic effects.
ALORA (estradiol vaginal ring) is contraindicated in pregnancy. First trimester: estrogen exposure is associated with a risk of vaginal adenosis and clear cell adenocarcinoma in female offspring, as well as congenital anomalies including cardiac defects and limb reduction defects. Second and third trimesters: increased risk of fetal genital abnormalities and potential for long-term reproductive tract effects. Estrogens are not indicated for use during pregnancy.
ANDROID-F contains methyltestosterone, a synthetic androgen. Androgens are teratogenic in humans. In first trimester: masculinization of female fetus, including clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimesters: continued virilization of female fetus; no increased risk of malformations in male fetuses. Contraindicated in pregnancy.
Estradiol is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.1-0.2. ALORA may reduce milk production and quality due to estrogenic effects. Use during breastfeeding is not recommended. If used, monitor the infant for signs of estrogen exposure such as breast enlargement or vaginal bleeding.
Methyltestosterone is excreted in breast milk. No specific M/P ratio available. May cause virilization in female infants and precocious development in male infants. Breastfeeding is contraindicated during therapy.
ALORA is contraindicated in pregnancy; no dosing adjustments are applicable. The physiological increase in estrogen-binding proteins and hepatic clearance during pregnancy would theoretically reduce efficacy if used, but use is prohibited due to teratogenicity.
ANDROID-F is contraindicated in pregnancy; no dosing recommendations for use in pregnancy. No established dose adjustments exist as the drug should not be administered.
ALORA 0.03% estradiol vaginal cream is indicated for atrophic vaginitis. Apply 1-2 g daily for 2 weeks, then taper. May cause endometrial hyperplasia if used without progestin in women with intact uterus. Avoid in breast cancer history.
Android-F is a brand of methyltestosterone, an androgen used primarily for male hypogonadism. Monitor liver function due to potential hepatotoxicity. Avoid in males with breast or prostate cancer. Use with caution in older patients due to increased risk of prostatic hypertrophy. May suppress clotting factors II, V, VII, and X.
Use the measured applicator for correct dose.,Apply cream at bedtime for best absorption.,Wash applicator after each use with soap and water.,Report any abnormal vaginal bleeding immediately.,Do not use if allergic to estrogens.
Take exactly as prescribed; do not increase dose or frequency.,Report any signs of liver problems (yellowing eyes/skin, dark urine, persistent nausea) immediately.,Women should report hoarseness, acne, or menstrual changes.,Men should report frequent or persistent erections, or breast swelling/tenderness.,May cause decreased sperm count in men; discuss family planning.,Avoid concurrent use with other medications without consulting doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALORA vs ANDROID-F, answered by our medical review team.
ALORA is a Estrogen that works by Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.. ANDROID-F is a Androgen/Estrogen Combination that works by Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALORA and ANDROID-F depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALORA is: Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.. The standard adult dose of ANDROID-F is: Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALORA and ANDROID-F in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALORA is classified as Category C. ALORA (estradiol vaginal ring) is contraindicated in pregnancy. First trimester: estrogen exposure is associated with a risk of vaginal adenosis and clear cell adenocarcinoma in fe. ANDROID-F is classified as Category C. ANDROID-F contains methyltestosterone, a synthetic androgen. Androgens are teratogenic in humans. In first trimester: masculinization of female fetus, including clitoromegaly, labi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.